Verge is focused on developing therapeutics for neurological diseases using human genomics to accelerate drug discovery. Verge has created a proprietary all-in-human platform, generating one of the field's largest and most comprehensive databases of ALS (amyotrophic lateral sclerosis) and Parkinson's Disease patient genomic data. The Company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson's disease toward the clinic.